Download PDF
Planta Med 2012; 78(08): 747-754
DOI: 10.1055/s-0031-1298434
Perspectives
Georg Thieme Verlag KG Stuttgart · New York

What Is the Best Strategy for Preclinical Testing of Botanicals? A Critical Perspective

Veronika Butterweck
1   Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
,
Adolf Nahrstedt
2   Institute of Pharmaceutical Biology and Phytochemistry, Westf. Wilhelms-University, Münster, Germany
› Author Affiliations
Further Information

Publication History

received 07 January 2012
revised 29 February 2012

accepted 12 March 2012

Publication Date:
12 April 2012 (online)

   Permissions and Reprints

Abstract

The development of a new drug is generally marked by a number of preclinical investigations in a sequential order with regard to contents and logic. However, ethnopharmacology often uses the “reverse pharmacology” approach, which is based on anecdotal therapeutic effects of plants in ancient texts or based on the empirical knowledge of traditional healers. While this approach could successfully lead to new therapeutic applications by using sophisticated techniques and appropriate bioassays in a logical order, unfortunately there is an exponentially increasing number of reports of pharmacological effects of botanical extracts with insignificant bioactivities obtained in often irrelevant in vitro bioassays. The interpretation based on in vitro data can only be misleading since the pharmacokinetic properties of a compound are ignored, unacceptable high dosages of extracts are tested, or metabolism to inactive metabolites is not considered. Further, many natural products are prodrugs that need to be metabolized in vivo by the intestinal microflora or by mammalian phase I/II metabolism. Frequently, attempts are made to master poor pharmacokinetics by administering the extract intraperitoneally or intravenously, clearly moving away from the traditional oral application. In this review article, it is proposed that preclinical testing strategies of botanicals should start with the in vivo examination of extracts in relevant animal models to substantiate the ethnopharmacological/ethnopharmaceutical use, followed by bioguided fractionation processes using an adequate in vitro model, further followed by pharmacokinetic studies and final in vivo testing of isolated compounds. With our article we would like to encourage authors, reviewers and editors to implement this strategy for the design of experiments and for the reviewing and editing process of manuscripts.

Key words

preclinical testing - ethnopharmacology - ethnopharmacy - botanicals - in vivo - in vitro - dosing - application
 

  • References

  • 1 McChesney JD, Venkataraman SK, Henri JT. Plant natural products: back to the future or into extinction?. Phytochemistry 2007; 68: 2015-2022
    CrossrefPubMedGoogle Scholar
  • 2 Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981–2002. J Nat Prod 2003; 66: 1022-1037
    CrossrefPubMedGoogle Scholar
  • 3 Kohn A. Fortune or failure: missed opportunities and chance discoveries. In: Roberts RM, editor Serendipity: accidental discoveries in science. New York: Wiley; 1989: 123-125
    Google Scholar
  • 4 Taylor L. Pharma R & D spend, NME launches slumped in 2010: study. Available at http://www.pharmatimes.com/article/11-06-28/Pharma_R_D_spend_NME_launches_slumped_in_2010_study.aspx Accessed January 2012
    PubMedGoogle Scholar
  • 5 Malone M. The pharmacological evaluation of natural products – general and specific approaches to screening ethnopharmaceuticals. J Ethnopharmacol 1983; 8: 127-147
    CrossrefPubMedGoogle Scholar
  • 6 Olejniczak K, Guenzel P, Bass R. Preclinical testing strategies. Drug Inf J 2001; 35: 321-336
    CrossrefPubMedGoogle Scholar
  • 7 Patwardhan B, Mashelkar RA. Traditional medicine-inspired approaches to drug discovery: can Ayurveda show the way forward?. Drug Discov Today 2009; 14: 804-811
    CrossrefPubMedGoogle Scholar
  • 8 Heinrich M. Ethnopharmacology in the 21st century – grand challenges. Front Pharmacol 2010; 1: 8
    PubMedGoogle Scholar
  • 9 Gertsch J. How scientific is the science in ethnopharmacology? Historical perspectives and epistemological problems. J Ethnopharmacol 2009; 122: 177-183
    CrossrefPubMedGoogle Scholar
  • 10 Kroll DJ, Oberlies NH. The impact of newly proposed dietary supplement manufacturing guidelines on patient safety and clinical trial outcomes. Focus Alternative Compl Ther 2003; 8: 302-306
    PubMedGoogle Scholar
  • 11 Vogel HG, Vogel W. Drug discovery and evaluation. New York: Springer; 2002
    CrossrefGoogle Scholar
  • 12 ICH Harmonized Tripartite Guideline. Safety pharmacology studies for human pharmaceuticals S7A. Available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf Accessed January 2012
    PubMedGoogle Scholar
  • 13 Adeyemi OO, Akindele AJ, Yemitan OK, Aigbe FR, Fagbo FI. Anticonvulsant, anxiolytic and sedative activities of the aqueous root extract of Securidaca longepedunculata Fresen. J Ethnopharmacol 2010; 130: 191-195
    CrossrefPubMedGoogle Scholar
  • 14 Rodriguez-Burford C, Oelschlager DK, Talley LI, Barnes MN, Partridge EE, Grizzle WE. The use of dimethylsulfoxide as a vehicle in cell culture experiments using ovarian carcinoma cell lines. Biotech Histochem 2003; 78: 17-21
    CrossrefPubMedGoogle Scholar
  • 15 Lison D, Huaux F. In vitro studies: Ups and downs of cellular uptake. Nat Nanotechnol 2011; 6: 332-333
    CrossrefPubMedGoogle Scholar
  • 16 Subramanian R, Asmawi MZ, Sadikun A. In vitro alpha-glucosidase and alpha-amylase enzyme inhibitory effects of Andrographis paniculata extract and andrographolide. Acta Biochim Pol 2008; 55: 391-398
    PubMedGoogle Scholar
  • 17 Matsui T, Kobayashi M, Hayashida S, Matsumoto K. Luteolin, a flavone, does not suppress postprandial glucose absorption through an inhibition of alpha-glucosidase action. Biosci Biotechnol Biochem 2002; 66: 689-692
    CrossrefPubMedGoogle Scholar
  • 18 Palu A, Deng S, West B, Jensen J. Xanthine oxidase inhibiting effects of noni (Morinda citrifolia) fruit juice. Phytother Res 2009; 23: 1790-1791
    CrossrefPubMedGoogle Scholar
  • 19 Verpoorte R. Setting standards!. J Ethnopharmacol 2006; 106: 289
    CrossrefPubMedGoogle Scholar
  • 20 Cos P, Vlietinck AJ, Berghe DV, Maes L. Anti-infective potential of natural products: how to develop a stronger in vitro ʼproof-of-conceptʼ. J Ethnopharmacol 2006; 106: 290-302
    CrossrefPubMedGoogle Scholar
  • 21 Sarawek S, Feistel B, Pischel I, Butterweck V. Flavonoids of Cynara scolymus possess potent xanthinoxidase inhibitory activity in vitro but are devoid of hypouricemic effects in rats after oral application. Planta Med 2008; 74: 221-227
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Sarawek S, Derendorf H, Butterweck V. Pharmacokinetics of luteolin and metabolites in rats. Nat Prod Commun 2008; 3: 2029-2036
    PubMedGoogle Scholar
  • 23 Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661
    CrossrefPubMedGoogle Scholar
  • 24 Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-342
    CrossrefPubMedGoogle Scholar
  • 25 Center for Drug Evaluation and Research, Center for Biological and Research. Estimating the safe and starting dose in clinical trials for therapeutics in adult healthy volunteers. Rockville, Maryland, USA: US Food and Drug Administration; 2002
    Google Scholar
  • 26 Nebendahl K, Hauff P. Drug administration. In: Kiessling F, Pichler BJ, Hauff P, editors Small animal imaging. Heidelberg: Springer; 2011: 93-119
    CrossrefGoogle Scholar
  • 27 Svendsen O. Ethics and animal welfare related to in vivo pharmacology and toxicology in laboratory animals. Basic Clin Pharmacol Toxicol 2005; 97: 197-199
    CrossrefPubMedGoogle Scholar
  • 28 Claassen V. Neglected factors in pharmacology and neuroscience research. In: Huston JP, editor Techniques in the behavioural and neural sciences. Amsterdam: Elsevier; 1994: 46-58
    Google Scholar
  • 29 Gotloib L, Wajsbrot V, Shostak A. A short review of experimental peritoneal sclerosis: from mice to men. Int J Artif Organs 2005; 28: 97-104
    PubMedGoogle Scholar
  • 30 Ryabinin AE, Wang YM, Finn DA. Different levels of Fos immunoreactivity after repeated handling and injection stress in two inbred strains of mice. Pharmacol Biochem Behav 1999; 63: 143-151
    CrossrefPubMedGoogle Scholar
  • 31 Wright DM, Lincoln DW. Stress-induced analgesia evoked by intraperitoneal injection of hypertonic saline: evidence for its occurrence in vasopressin deficient rats. Physiol Behav 1985; 34: 691-695
    CrossrefPubMedGoogle Scholar
  • 32 de-Paris F, Neves G, Salgueiro JB, Quevedo J, Izquierdo I, Rates SM. Psychopharmacological screening of Pfaffia glomerata Spreng. (Amaranthaceae) in rodents. J Ethnopharmacol 2000; 73: 261-269
    CrossrefPubMedGoogle Scholar
  • 33 Akao T, Yoshino T, Kobashi K, Hattori M. Evaluation of salicin as an antipyretic prodrug that does not cause gastric injury. Planta Med 2002; 68: 714-718
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Atkinson C, Berman S, Humbert O, Lampe JW. In vitro incubation of human feces with daidzein and antibiotics suggests interindividual differences in the bacteria responsible for equol production. J Nutr 2004; 134: 596-599
    PubMedGoogle Scholar
  • 35 Mullen W, Rouanet JM, Auger C, Teissedre PL, Caldwell ST, Hartley RC, Lean ME, Edwards CA, Crozier A. Bioavailability of [2-(14)C]quercetin-4′-glucoside in rats. J Agric Food Chem 2008; 56: 12127-12137
    CrossrefPubMedGoogle Scholar
  • 36 Aura AM, OʼLeary KA, Williamson G, Ojala M, Bailey M, Puupponen-Pimia R, Nuutila AM, Oksman-Caldentey KM, Poutanen K. Quercetin derivatives are deconjugated and converted to hydroxyphenylacetic acids but not methylated by human fecal flora in vitro . J Agric Food Chem 2002; 50: 1725-1730
    CrossrefPubMedGoogle Scholar
  • 37 Blaut M, Schoefer L, Braune A. Transformation of flavonoids by intestinal microorganisms. Int J Vitam Nutr Res 2003; 73: 79-87
    CrossrefPubMedGoogle Scholar
  • 38 Griffiths LA, Smith GE. Metabolism of myricetin and related compounds in the rat. Metabolite formation in vivo and by the intestinal microflora in vitro . Biochem J 1972; 130: 141-151
    PubMedGoogle Scholar
  • 39 Keppler K, Hein EM, Humpf HU. Metabolism of quercetin and rutin by the pig caecal microflora prepared by freeze-preservation. Mol Nutr Food Res 2006; 50: 686-695
    CrossrefPubMedGoogle Scholar
  • 40 Labib S, Hummel S, Richling E, Humpf HU, Schreier P. Use of the pig caecum model to mimic the human intestinal metabolism of hispidulin and related compounds. Mol Nutr Food Res 2006; 50: 78-86
    CrossrefPubMedGoogle Scholar
  • 41 Scalbert A, Morand C, Manach C, Remesy C. Absorption and metabolism of polyphenols in the gut and impact on health. Biomed Pharmacother 2002; 56: 276-282
    CrossrefPubMedGoogle Scholar
  • 42 Vissiennon C, Nieber K, Kelber O, Butterweck V. Route of administration determines the anxiolytic activity of the flavonols kaempferol, quercetin and myricetin – are they prodrugs?. J Nutr Biochem in press
    PubMedGoogle Scholar
  • 43 Butterweck V, Lieflander-Wulf U, Winterhoff H, Nahrstedt A. Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats. Planta Med 2003; 69: 189-192
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Nahrstedt A, Butterweck V. Lessons learned from herbal medicinal products: the example of St. Johnʼs Wort. J Nat Prod 2010; 73: 1015-1021
    CrossrefPubMedGoogle Scholar
  • 45 Gertsch J. Botanical drugs, synergy, and network pharmacology: forth and back to intelligent mixtures. Planta Med 2011; 77: 1086-1098
    Article in Thieme ConnectPubMedGoogle Scholar